FINWIRES · TerminalLIVE
FINWIRES

Ford Motor Shares Rise After Morgan Stanley Highlights Energy-Storage Deal Potential

By

Ford Motor (F) shares rose 13% in Wednesday trading after Morgan Stanley said the company had a "fairly high likelihood" of signing energy-storage solutions supply agreements with large commercial customers, including hyperscalers, in the next few months.

Ford's licensing agreement with China's Contemporary Amperex Technology, or CATL, is a "key competitive differentiator" that is not fully understood by investors and has been overlooked, Morgan Stanley said Tuesday in a report.

The technology licensed from CATL, which is the world's premier energy storage manufacturer, offers Ford the opportunity to allocate capital into a strategic growth area and participate in a fast-growing and relatively high-margin energy-storage market, the report said.

Morgan Stanley estimates Ford Energy could generate $500 million to $600 million of run-rate EBIT at 20 GWh of production, with potential upside if capacity expands to meet demand.

Ford is set to become one of the US suppliers compliant with the Foreign Entity of Concern rule with proven technology, allowing it to qualify for a 30% investment tax credit, which is an underappreciated competitive advantage, the report said.

Morgan Stanley has an equal-weight rating on Ford stock with a price target of $14.

Price: $13.59, Change: $+1.60, Percent Change: +13.30%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP